HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to colon cancer progression

Cancer Letters

Volumn 355, Issue 1, 2014, Pages 130-140

  Li, Yang ^a   Zhao, Zhongxin ^a   Xu, Chuanhui ^b   Zhou, Zhuqing ^a   Zhu, Zhe ^a   You, Tiangeng ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Epithelial to mesenchymal transition (EMT); HMGA2; Metastasis; Proliferation; Slug

Indexed keywords

CELL MARKER; HIGH MOBILITY GROUP A2 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SLUG; TRANSFORMING GROWTH FACTOR BETA; MITOGEN ACTIVATED PROTEIN KINASE; SNAIL FAMILY TRANSCRIPTION FACTORS; TGFB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRUS INFECTION; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; CELL MOTION; COLON TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HT 29 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROMOTER REGION; RNA INTERFERENCE; TIME; TUMOR VOLUME;

ANIMALS; BINDING SITES; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HT29 CELLS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN; UP-REGULATION;

EID: 84908005389     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.007     Document Type: Article

References (46)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin 2012, 62(2012):10-29.
3. McLeod H.L., Murray G.I. Tumour markers of prognosis in colorectal cancer. Br. J. Cancer 1999, 79:191-203.
4. Eschrich S., Yang I., Bloom G., Kwong K.Y., Boulware D., Cantor A., et al. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol 2005, 23:3526-3535.
5. Hirakawa M., Takimoto R., Tamura F., Yoshida M., Ono M., Murase K., et al. Fucosylated TGF-beta receptors transduces a signal for epithelial-mesenchymal transition in colorectal cancer cells. Br. J. Cancer 2014, 110:156-163.
6. Liu R., Li J., Xie K., Zhang T., Lei Y., Chen Y., et al. FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer. Cancer Res 2013, 73:5926-5935.
7. Roy N., Bommi P.V., Bhat U.G., Bhattacharjee S., Elangovan I., Li J., et al. DDB2 suppresses epithelial-to-mesenchymal transition in colon cancer. Cancer Res 2013, 73:3771-3782.
8. Paek A.R., Lee C.H., You H.J. A role of zinc-finger protein 143 for cancer cell migration and invasion through ZEB1 and E-cadherin in colon cancer cells. Mol. Carcinog 2014, 53(Suppl. 1):E161-E168.
9. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5:744-749.
10. Escriva M., Peiro S., Herranz N., Villagrasa P., Dave N., Montserrat-Sentis B., et al. Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol. Cell. Biol 2008, 28:1528-1540.
11. Thuault S., Valcourt U., Petersen M., Manfioletti G., Heldin C.H., Moustakas A. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J. Cell Biol 2006, 174:175-183.
12. Petz M., Them N.C., Huber H., Mikulits W. PDGF enhances IRES-mediated translation of Laminin B1 by cytoplasmic accumulation of La during epithelial to mesenchymal transition. Nucleic Acids Res 2012, 40:9738-9749.
13. Davies M., Robinson M., Smith E., Huntley S., Prime S., Paterson I. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. J. Cell. Biochem 2005, 95:918-931.
14. Roth A.D., Tejpar S., Delorenzi M., Yan P., Fiocca R., Klingbiel D., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol 2010, 28:466-474.
15. Simi L., Pratesi N., Vignoli M., Sestini R., Cianchi F., Valanzano R., et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am. J. Clin. Pathol 2008, 130:247-253.
16. Minoo P., Moyer M.P., Jass J.R. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J. Pathol 2007, 212:124-133.
17. Rosenberg D.W., Yang S., Pleau D.C., Greenspan E.J., Stevens R.G., Rajan T.V., et al. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res 2007, 67:3551-3554.
18. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 2007, 7:415-428.
19. Savagner P., Karavanova I., Perantoni A., Thiery J.P., Yamada K.M. Slug mRNA is expressed by specific mesodermal derivatives during rodent organogenesis. Dev. Dyn 1998, 213:182-187.
20. Shioiri M., Shida T., Koda K., Oda K., Seike K., Nishimura M., et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br. J. Cancer 2006, 94:1816-1822.
21. Shih J.Y., Tsai M.F., Chang T.H., Chang Y.L., Yuan A., Yu C.J., et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin. Cancer Res 2005, 11:8070-8078.
22. Shih J.Y., Yang P.C. The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011, 32:1299-1304.
23. Fusco A., Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 2007, 7:899-910.
24. Fedele M., Visone R., De Martino I., Troncone G., Palmieri D., Battista S., et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006, 9:459-471.
25. Zhou X., Benson K.F., Ashar H.R., Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995, 376:771-774.
26. Weedon M.N., Lettre G., Freathy R.M., Lindgren C.M., Voight B.F., Perry J.R., et al. A common variant of HMGA2 is associated with adult and childhood height in the general population. Nat. Genet 2007, 39:1245-1250.
27. Huang M.L., Chen C.C., Chang L.C. Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer. Int. J. Colorectal Dis 2009, 24:1281-1286.
28. Rogalla P., Drechsler K., Kazmierczak B., Rippe V., Bonk U., Bullerdiek J. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol. Carcinog 1997, 19:153-156.
29. Langelotz C., Schmid P., Jakob C., Heider U., Wernecke K.D., Possinger K., et al. Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br. J. Cancer 2003, 88:1406-1410.
30. Wang X., Liu X., Li A.Y., Chen L., Lai L., Lin H.H., et al. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin. Cancer Res 2011, 17:2570-2580.
31. Sarhadi V.K., Wikman H., Salmenkivi K., Kuosma E., Sioris T., Salo J., et al. Increased expression of high mobility group A proteins in lung cancer. J. Pathol 2006, 209:206-212.
32. Sun M., Song C.X., Huang H., Frankenberger C.A., Sankarasharma D., Gomes S., et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc. Natl Acad. Sci. U.S.A. 2013, 110:9920-9925.
33. De Martino I., Visone R., Wierinckx A., Palmieri D., Ferraro A., Cappabianca P., et al. HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res 2009, 69:1844-1850.
34. Tessari M.A., Gostissa M., Altamura S., Sgarra R., Rustighi A., Salvagno C., et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol. Cell. Biol 2003, 23:9104-9116.
35. Valcourt U., Kowanetz M., Niimi H., Heldin C.H., Moustakas A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol. Biol. Cell 2005, 16:1987-2002.
36. Ye Q., Cai W., Zheng Y., Evers B.M., She Q.B. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene 2014, 33:1828-1839.
37. Motoyama K., Inoue H., Nakamura Y., Uetake H., Sugihara K., Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin. Cancer Res 2008, 14:2334-2340.
38. Morishita A., Zaidi M.R., Mitoro A., Sankarasharma D., Szabolcs M., Okada Y., et al. HMGA2 is a driver of tumor metastasis. Cancer Res 2013, 73:4289-4299.
39. Watanabe S., Ueda Y., Akaboshi S., Hino Y., Sekita Y., Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am. J. Pathol 2009, 174:854-868.
40. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
41. Wen F.C., Chang T.W., Tseng Y.L., Lee J.C., Chang M.C. hRAD9 functions as a tumor suppressor by inducing p21-dependent senescence and suppressing epithelial-mesenchymal transition through inhibition of Slug transcription. Carcinogenesis 2014, 35:1481-1490.
42. Wend P., Runke S., Wend K., Anchondo B., Yesayan M., Jardon M., et al. WNT10B/beta-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Mol. Med 2013, 5:264-279.
43. Li Z., Zhang Y., Ramanujan K., Ma Y., Kirsch D.G., Glass D.J. Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway. Cancer Res 2013, 73:3041-3050.
44. Oram K.F., Carver E.A., Gridley T. Slug expression during organogenesis in mice. Anat. Rec. A. Discov Mol Cell Evol. Biol 2003, 271:189-191.
45. Alves C.C., Carneiro F., Hoefler H., Becker K.F. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front. Biosci. (Landmark Ed.) 2009, 14:3035-3050.
46. Tan E.J., Thuault S., Caja L., Carletti T., Heldin C.H., Moustakas A. Regulation of transcription factor Twist expression by the DNA architectural protein high mobility group A2 during epithelial-to-mesenchymal transition. J. Biol. Chem 2012, 287:7134-7145.